Ontario-led Team Receives $4.7M from Movember to Develop Dx to Guide Prostate Cancer Treatment | GenomeWeb

NEW YORK (GenomeWeb) – A research team led by scientists at the Ontario Institute for Cancer Research have received a C$5 million (US$4.7 million) grant from the Movember Foundation to develop diagnostic molecular markers that physicians could use to make treatment decisions for their prostate cancer patients.

Called PRONTO, the project was funded by a Movember Team Grant that was awarded by Prostate Cancer Canada, PCC said on Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.